Madrigal Pharmaceuticals (MDGL) Stock Forecast & Price Target

Compare

1,314 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

MDGL Analyst Ratings

Strong Buy

11 Buy

1 Hold

0 Sell

Based on 12 analysts giving stock ratings to

Madrigal

Pharmaceuticals

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

MDGL Stock 12 Month Forecast

Average Price Target

$561.73

▼(-3.06% Downside)

Based on 12 Wall Street analysts offering 12 month price targets for Madrigal Pharmaceuticals in the last 3 months. The average price target is $561.73 with a high forecast of $650.00 and a low forecast of $445.00. The average price target represents a -3.06% change from the last price of $579.45.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"271":"$271","366":"$366","461":"$461","556":"$556","651":"$651"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":650,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$650.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":561.73,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$561.73</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":445,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$445.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[271,366,461,556,651],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Feb<br/>2025","6":"May<br/>2025","9":"Aug<br/>2025","12":"Nov<br/>2025","25":"Nov<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,418.9,436.67692307692306,454.45384615384614,472.2307692307692,490.0076923076923,507.7846153846154,525.5615384615385,543.3384615384615,561.1153846153846,578.8923076923077,596.6692307692308,614.4461538461538,632.2230769230769,{"y":650,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,418.9,429.88692307692304,440.87384615384616,451.8607692307692,462.8476923076923,473.8346153846154,484.82153846153847,495.80846153846153,506.7953846153846,517.7823076923077,528.7692307692307,539.7561538461539,550.743076923077,{"y":561.73,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,418.9,420.9076923076923,422.9153846153846,424.9230769230769,426.9307692307692,428.9384615384615,430.94615384615383,432.95384615384614,434.96153846153845,436.96923076923076,438.9769230769231,440.9846153846154,442.9923076923077,{"y":445,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":319.58,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 25,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":318.55,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 13, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":308.57,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 22,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 20, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 5</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":334.8,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 27,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 13, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 5</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":341.27,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 27,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 5</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":323.98,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":327.7,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":272.67,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":300.16,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 23,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 5</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":302.17,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 30,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":436.11,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 31,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":449.14,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 24,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":418.9,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 21,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target$650.00

Average Price Target$561.73

Lowest Price Target$445.00

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Andrew Fein

H.C. Wainwright

$568→$620

Buy

7.00%

Upside

Reiterated

11/21/25

Strong Adoption and Market Expansion Drive Buy Rating for Madrigal Pharmaceuticals' RezdiffraValuation and Risks. Based on AASLD data and KOL commentary on current and expected Rezdiffra penetration, we increase our PT to $620 and reiterate our Buy rating. We estimate the intrinsic value of MDGL in our rNPV model as the sum of Rezdiffra in MASH with moderate-to-advanced fibrosis (F2-F3) in both the U.S. and EU at $588.23 per share; and in MASH with compensated cirrhosis in both the U.S. and EU at $32.01 per share (75% PoS). Our revenue models project peak sales of nearly $7.2B in 2033 in fibrotic MASH and about $948.9M in 2033 in cirrhotic MASH.

Jay Olson

Oppenheimer

$600→$650

Buy

12.18%

Upside

Reiterated

11/20/25

Madrigal Pharmaceuticals price target raised to $650 from $600 at OppenheimerMadrigal Pharmaceuticals price target raised to $650 from $600 at Oppenheimer

Srikripa Devarakonda

Truist Financial

$580→$640

Buy

10.45%

Upside

Initiated

11/19/25

Madrigal Pharmaceuticals (MDGL) Has a New Rating from Truist FinancialMDGL Increased conviction in MASH F4; PT $640 from $580. We remain Buyers of MDGL and raise our PT to $640.

Edward Nash

Canaccord Genuity

$526→$587

Buy

1.30%

Upside

Reiterated

11/14/25

Optimistic Buy Rating for Madrigal Pharmaceuticals Driven by Strong Drug Performance and Strategic European ExpansionWe have further increased our R&D and SG&A estimates going forward based on costs related to running the combo clinical trials as well the expansion into Europe and more specifically to our model expanding the detailing to endocrinologists, which we had not incorporated into our model previously.

Yasmeen Rahimi

Piper Sandler

$540

Buy

-6.81%

Downside

Reiterated

11/11/25

Madrigal Pharmaceuticals (MDGL) Gets a Buy from Piper Sandler

Jonathan Wolleben

Citizens JMP

$485→$527

Buy

-9.05%

Downside

Reiterated

11/05/25

Madrigal Pharmaceuticals price target raised to $527 from $485 at Citizens JMPMadrigal Pharmaceuticals price target raised to $527 from $485 at Citizens JMP

Jason Zemansky

Bank of America Securities

$266→$445

Hold

-23.20%

Downside

Upgraded

11/05/25

Madrigal Pharmaceuticals upgraded to Neutral from Underperform at BofAMadrigal Pharmaceuticals upgraded to Neutral from Underperform at BofA

William Wood

B. Riley Securities

$560

Buy

-3.36%

Downside

Reiterated

11/05/25

Madrigal Pharmaceuticals (MDGL) Receives a Buy from B. Riley Securities

Ritu Baral

TD Cowen

$554

Buy

-4.39%

Downside

Reiterated

11/04/25

Madrigal Pharmaceuticals: Strong Market Performance and Strategic Positioning Drive Buy Rating

Prakhar Agrawal

Cantor Fitzgerald

―

Buy

―

Upgraded

11/04/25

Madrigal Pharmaceuticals upgraded to Overweight from Neutral at Cantor FitzgeraldMadrigal Pharmaceuticals upgraded to Overweight from Neutral at Cantor Fitzgerald

Kaveri Pohlman

Clear Street

$431→$533

Buy

-8.02%

Downside

Reiterated

11/04/25

Madrigal Pharmaceuticals price target raised to $533 from $431 at Clear StreetMadrigal Pharmaceuticals price target raised to $533 from $431 at Clear Street

Eliana Merle

UBS

$523

Buy

-9.74%

Downside

Reiterated

09/24/25

Madrigal Pharmaceuticals (MDGL) Gets a Buy from UBS

Michael DiFiore

Evercore ISI

$392

Buy

-32.35%

Downside

Initiated

08/22/25

Evercore ISI Sticks to Its Buy Rating for Madrigal Pharmaceuticals (MDGL)

Thomas Smith

Leerink Partners

―

Buy

―

Reiterated

08/19/25

Madrigal Pharmaceuticals: Pioneering MASH Treatment with Rezdiffra's European Market Breakthrough

David Lebowitz

Citi

$505

Buy

-12.85%

Downside

Assigned

08/19/25

Buy Rating Affirmed for Madrigal Pharmaceuticals Amid Market Expansion Opportunities

Analyst Type

Any

Human Analysts

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Andrew Fein

H.C. Wainwright

$568→$620

Buy

7.00%

Upside

Reiterated

11/21/25

Jay Olson

Oppenheimer

$600→$650

Buy

12.18%

Upside

Reiterated

11/20/25

Madrigal Pharmaceuticals price target raised to $650 from $600 at OppenheimerMadrigal Pharmaceuticals price target raised to $650 from $600 at Oppenheimer

Srikripa Devarakonda

Truist Financial

$580→$640

Buy

10.45%

Upside

Initiated

11/19/25

Madrigal Pharmaceuticals (MDGL) Has a New Rating from Truist FinancialMDGL Increased conviction in MASH F4; PT $640 from $580. We remain Buyers of MDGL and raise our PT to $640.

Edward Nash

Canaccord Genuity

$526→$587

Buy

1.30%

Upside

Reiterated

11/14/25

Yasmeen Rahimi

Piper Sandler

$540

Buy

-6.81%

Downside

Reiterated

11/11/25

Madrigal Pharmaceuticals (MDGL) Gets a Buy from Piper Sandler

Jonathan Wolleben

Citizens JMP

$485→$527

Buy

-9.05%

Downside

Reiterated

11/05/25

Madrigal Pharmaceuticals price target raised to $527 from $485 at Citizens JMPMadrigal Pharmaceuticals price target raised to $527 from $485 at Citizens JMP

Jason Zemansky

Bank of America Securities

$266→$445

Hold

-23.20%

Downside

Upgraded

11/05/25

Madrigal Pharmaceuticals upgraded to Neutral from Underperform at BofAMadrigal Pharmaceuticals upgraded to Neutral from Underperform at BofA

William Wood

B. Riley Securities

$560

Buy

-3.36%

Downside

Reiterated

11/05/25

Madrigal Pharmaceuticals (MDGL) Receives a Buy from B. Riley Securities

Ritu Baral

TD Cowen

$554

Buy

-4.39%

Downside

Reiterated

11/04/25

Madrigal Pharmaceuticals: Strong Market Performance and Strategic Positioning Drive Buy Rating

Prakhar Agrawal

Cantor Fitzgerald

―

Buy

―

Upgraded

11/04/25

Madrigal Pharmaceuticals upgraded to Overweight from Neutral at Cantor FitzgeraldMadrigal Pharmaceuticals upgraded to Overweight from Neutral at Cantor Fitzgerald

Kaveri Pohlman

Clear Street

$431→$533

Buy

-8.02%

Downside

Reiterated

11/04/25

Madrigal Pharmaceuticals price target raised to $533 from $431 at Clear StreetMadrigal Pharmaceuticals price target raised to $533 from $431 at Clear Street

Eliana Merle

UBS

$523

Buy

-9.74%

Downside

Reiterated

09/24/25

Madrigal Pharmaceuticals (MDGL) Gets a Buy from UBS

Michael DiFiore

Evercore ISI

$392

Buy

-32.35%

Downside

Initiated

08/22/25

Evercore ISI Sticks to Its Buy Rating for Madrigal Pharmaceuticals (MDGL)

Thomas Smith

Leerink Partners

―

Buy

―

Reiterated

08/19/25

Madrigal Pharmaceuticals: Pioneering MASH Treatment with Rezdiffra's European Market Breakthrough

David Lebowitz

Citi

$505

Buy

-12.85%

Downside

Assigned

08/19/25

Buy Rating Affirmed for Madrigal Pharmaceuticals Amid Market Expansion Opportunities

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

xxx

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Madrigal Pharmaceuticals

1 Month

xxx

Success Rate

11/15 ratings generated profit

Average Return

+30.33%

reiterated a xxx

rating 4 months ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 1 Month would result in 73.33% of your transactions generating a profit, with an average return of +30.33% per trade.

3 Months

xxx

Success Rate

11/14 ratings generated profit

Average Return

+14.96%

reiterated a xxx

rating 9 months ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 3 Months would result in 78.57% of your transactions generating a profit, with an average return of +14.96% per trade.

1 Year

Ritu BaralTD Cowen

Success Rate

21/23 ratings generated profit

Average Return

+54.78%

reiterated a buy rating 30 days ago

Copying Ritu Baral's trades and holding each position for 1 Year would result in 91.30% of your transactions generating a profit, with an average return of +54.78% per trade.

2 Years

xxx

Success Rate

14/14 ratings generated profit

Average Return

+151.85%

reiterated a xxx

rating 9 months ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 2 Years would result in 100.00% of your transactions generating a profit, with an average return of +151.85% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

MDGL Analyst Recommendation Trends

Rating

Jul 25

Aug 25

Sep 25

Oct 25

Nov 25

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, MDGL has received 21 Buy Ratings, 1 Hold Ratings, and 0 Sell Ratings. MDGL average Analyst price target in the past 3 months is 561.73.

Each month's total comprises the sum of three months' worth of ratings.

MDGL Financial Forecast

MDGL Earnings Forecast

Next quarter’s earnings estimate for MDGL is -$0.68 with a range of -$6.09 to $1.96. The previous quarter’s EPS was -$5.08. MDGL beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.07% of the time in the same period. In the last calendar year MDGL has Performed in-line its overall industry.

MDGL Sales Forecast

Next quarter’s sales forecast for MDGL is $311.32M with a range of $290.10M to $320.10M. The previous quarter’s sales results were $287.27M. MDGL beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 47.62% of the time in the same period. In the last calendar year MDGL has Performed in-line its overall industry.

MDGL Stock Forecast FAQ

What is MDGL’s average 12-month price target, according to analysts?

Based on analyst ratings, Madrigal Pharmaceuticals Inc’s 12-month average price target is 561.73.

What is MDGL’s upside potential, based on the analysts’ average price target?

Currently there's no upside potential for MDGL, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is MDGL a Buy, Sell or Hold?

Madrigal Pharmaceuticals Inc has a consensus rating of Strong Buy which is based on 11 buy ratings, 1 hold ratings and 0 sell ratings.

What is Madrigal Pharmaceuticals Inc’s price target?

The average price target for Madrigal Pharmaceuticals Inc is 561.73. This is based on 12 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $650.00 ,the lowest forecast is $445.00. The average price target represents -3.06% Decrease from the current price of $579.45.

What do analysts say about Madrigal Pharmaceuticals Inc?

Madrigal Pharmaceuticals Inc’s analyst rating consensus is a Strong Buy. This is based on the ratings of 12 Wall Streets Analysts.

How can I buy shares of MDGL?

Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing

Madrigal Pharmaceuticals (MDGL) Stock Forecast & Price Target

MDGL Analyst Ratings

MDGL Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Madrigal Pharmaceuticals

MDGL Analyst Recommendation Trends

MDGL Financial Forecast

MDGL Earnings Forecast

MDGL Sales Forecast

MDGL Stock Forecast FAQ

Become an Expert with TipRanks Premium

Detailed List of Analyst Forecasts